The 🌎 burden of #MASH is staggering: 5.3% of adults face higher risks of cirrhosis, liver cancer & other complications as fibrosis progresses.
our latest study on MAESTRO-NASH resmetirom data & its real-world implications post-FDA approval www.nature.com/articles/s44... #SLDsummit

Thanks for highlighting our paper @dufourjf.bsky.social! Challenging to undertake these trials in ACLD but hopefully offers some potential utility, more from this cohort to come in our long term follow up analysis this summer 🤞

My take away is that immediately pre- surgery the Post-TIPSS group had worse MELD composites, whilst they had good PSM controlling at time point 6 months before, they were clearly less robust at time of intervention. What about matching with similar non-TIPSS MELD controls at time of op?